The American Board of Medical Genetics and Genomics (ABMGG) announces that Miriam (Mimi) Blitzer, PhD, will be stepping down as Chief Executive Officer at the end of 2024.
Dr. Blitzer has a long history with ABMGG which began as a question writer for certification examinations in the early 1990’s. In 1996, she was elected to the Board of Directors, during which she served several leadership roles that included Chair of the Board (2001-2002). Dr. Blitzer has served as CEO since the fall of 2009.
Leadership of many key activities has highlighted Dr. Blitzer’s productive tenure with the ABMGG. These include establishing ABMGG administration of the national in-training exams (ITE); development of the Laboratory Genetics and Genomics specialty and its approval by American Board of Medical Specialties (ABMS); approval and move of accreditation of the laboratory training programs to the Accreditation Council on Graduate Medical Education (ACGME); transition of the recertification process to continuing certification with longitudinal assessment (CertLink); and the transition to a new provider for the development and administration of the ABMGG certifying examination programs.
In addition to her many years of service to the ABMGG, Dr. Blitzer has completed terms on the boards of the American Society of Human Genetics and the Association of Professors in Human and Medical Genetics. Currently she serves on the Board of Directors of ABMS, their Committee on Continuing Certification (3C), and their Diversity, Equity, and Inclusion Task Force.
The ABMGG Board of Directors is conducting a national search to identify a candidate to succeed Dr. Blitzer and lead the ABMGG into the next exciting era for medical genetics and genomics.